We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TMO Stock Could Gain Following the Launch of EMPAD G2 Detector
Read MoreHide Full Article
Key Takeaways
Thermo Fisher launched EMPAD G2 to enable faster, detailed 4D STEM materials analysis in a single scan.
TMO's EMPAD G2 runs at 10,000 frames per second and supports advanced atomic-scale characterization.
Thermo Fisher integrates EMPAD G2 with Velox software to simplify analysis and improve repeatable results.
Thermo Fisher Scientific Inc. (TMO - Free Report) recently unveiled the Thermo Scientific EMPAD G2 detector to help researchers analyze materials in unprecedented detail. This development is expected to bolster the company’s Analytical Instruments segment.
TMO Stock Outlook Following the News
After the announcement, TMO shares dipped slightly by 0.8% last Thursday.
On a positive note, Thermo Fisher has steadily ramped up R&D investments in recent years, fueling new product launches and enhancing its portfolio. We expect the latest development to improve investor sentiment toward TMO stock and support its upward momentum in the near term.
Thermo Fisher has a market capitalization of $233.20 billion. The company’s earnings yield of 4% is well ahead of the industry’s -1.3% yield. It surpassed earnings estimates in each of the trailing four quarters, delivering an average surprise of 4.4%.
About TMO’s EMPAD G2 Detector
EMPAD G2 enables high-speed four-dimensional scanning transmission electron microscopy (4D STEM), an advanced form of electron microscopy. It aims to help researchers capture more information about materials in a single scan, recording both the strongest and weakest signals without sacrificing imaging speed or data quality.
The advanced 4D STEM technology offers faster, more reliable and user-friendly performance, helping researchers accelerate discoveries in semiconductors, energy and advanced materials while supporting the development of technologies with real-world applications.
Performance and Workflow of TMO’s EMPAD G2
EMPAD G2 runs at 10,000 frames per second (0.1 ms/frame), with exceptionally high single-frame dynamic range (>10???), single-electron sensitivity and operation across the full 30–300 kV range. EMPAD G2 supports advanced applications, ranging from strain mapping and differential phase contrast (DPC) to multi-slice electron ptychography for three-dimensional characterization at the atomic scale.
EMPAD G2 is also fully integrated with the user-friendly Thermo Scientific Velox software. Researchers can collect and analyze multiple types of data, including simultaneous 4D STEM and energy-dispersive x-ray spectroscopy (EDS) within a single workflow. This integration helps simplify advanced materials analysis and supports more reliable, repeatable results.
Image Source: Zacks Investment Research
Industry Prospects Favor TMO
Per a QYResearch report, the global 4D STEM market was valued at an estimated $68 million in 2024 and is projected to reach $110 million by 2031, reflecting a CAGR of 6.6% from 2025 to 2031.
As 4D STEM becomes more widely adopted in academic and industrial research, detector performance is becoming increasingly important. Researchers need to capture large volumes of information rapidly while accurately measuring signals ranging from extremely strong to extremely weak. EMPAD G2 is specifically designed to meet these demands, enabling researchers to obtain reliable quantitative information from a single acquisition.
TMO: Another Key Development
Thermo Fisher recently launched Thermo Scientific Orbitrap Isora Mass Spectrometer and Orbitrap Isora Pro Mass Spectrometer, the company’s first Orbitrap instruments with a dedicated isotope ratio analysis mode. Combined with the Thermo Scientific Vanquish Duo UHPLC System and new Isotope Discoverer Software, the instruments form an integrated workflow designed to make molecular-level isotope ratio analysis accessible to more laboratories and researchers worldwide.
TMO Stock Price Performance
In the past year, TMO shares have risen 25.3% against the industry’s 4.1% decline.
TMO’s Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #3 (Hold).
Globus Medical has an earnings yield of 5.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED’s shares have rallied 42.3% against the industry’s 6.3% decline over the past year.
Veracyte, sporting a Zacks Rank #1 at present, has an earnings yield of 4.6% against the industry’s negative 1.7% yield. Shares of the company have risen 38% against the industry’s 6.3% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
Illumina, presently carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 13% compared with the industry’s 23% growth. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 9.7%. ILMN’s shares have rallied 194.6% compared with the industry’s 24.6% growth over the past year.
View the Zacks #1 Rank List
Image: Bigstock
TMO Stock Could Gain Following the Launch of EMPAD G2 Detector
Key Takeaways
Thermo Fisher Scientific Inc. (TMO - Free Report) recently unveiled the Thermo Scientific EMPAD G2 detector to help researchers analyze materials in unprecedented detail. This development is expected to bolster the company’s Analytical Instruments segment.
TMO Stock Outlook Following the News
After the announcement, TMO shares dipped slightly by 0.8% last Thursday.
On a positive note, Thermo Fisher has steadily ramped up R&D investments in recent years, fueling new product launches and enhancing its portfolio. We expect the latest development to improve investor sentiment toward TMO stock and support its upward momentum in the near term.
Thermo Fisher has a market capitalization of $233.20 billion. The company’s earnings yield of 4% is well ahead of the industry’s -1.3% yield. It surpassed earnings estimates in each of the trailing four quarters, delivering an average surprise of 4.4%.
About TMO’s EMPAD G2 Detector
EMPAD G2 enables high-speed four-dimensional scanning transmission electron microscopy (4D STEM), an advanced form of electron microscopy. It aims to help researchers capture more information about materials in a single scan, recording both the strongest and weakest signals without sacrificing imaging speed or data quality.
The advanced 4D STEM technology offers faster, more reliable and user-friendly performance, helping researchers accelerate discoveries in semiconductors, energy and advanced materials while supporting the development of technologies with real-world applications.
Performance and Workflow of TMO’s EMPAD G2
EMPAD G2 runs at 10,000 frames per second (0.1 ms/frame), with exceptionally high single-frame dynamic range (>10???), single-electron sensitivity and operation across the full 30–300 kV range. EMPAD G2 supports advanced applications, ranging from strain mapping and differential phase contrast (DPC) to multi-slice electron ptychography for three-dimensional characterization at the atomic scale.
EMPAD G2 is also fully integrated with the user-friendly Thermo Scientific Velox software. Researchers can collect and analyze multiple types of data, including simultaneous 4D STEM and energy-dispersive x-ray spectroscopy (EDS) within a single workflow. This integration helps simplify advanced materials analysis and supports more reliable, repeatable results.
Image Source: Zacks Investment Research
Industry Prospects Favor TMO
Per a QYResearch report, the global 4D STEM market was valued at an estimated $68 million in 2024 and is projected to reach $110 million by 2031, reflecting a CAGR of 6.6% from 2025 to 2031.
As 4D STEM becomes more widely adopted in academic and industrial research, detector performance is becoming increasingly important. Researchers need to capture large volumes of information rapidly while accurately measuring signals ranging from extremely strong to extremely weak. EMPAD G2 is specifically designed to meet these demands, enabling researchers to obtain reliable quantitative information from a single acquisition.
TMO: Another Key Development
Thermo Fisher recently launched Thermo Scientific Orbitrap Isora Mass Spectrometer and Orbitrap Isora Pro Mass Spectrometer, the company’s first Orbitrap instruments with a dedicated isotope ratio analysis mode. Combined with the Thermo Scientific Vanquish Duo UHPLC System and new Isotope Discoverer Software, the instruments form an integrated workflow designed to make molecular-level isotope ratio analysis accessible to more laboratories and researchers worldwide.
TMO Stock Price Performance
In the past year, TMO shares have risen 25.3% against the industry’s 4.1% decline.
TMO’s Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and Illumina (ILMN - Free Report) .
Globus Medical has an earnings yield of 5.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED’s shares have rallied 42.3% against the industry’s 6.3% decline over the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Veracyte, sporting a Zacks Rank #1 at present, has an earnings yield of 4.6% against the industry’s negative 1.7% yield. Shares of the company have risen 38% against the industry’s 6.3% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
Illumina, presently carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 13% compared with the industry’s 23% growth. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 9.7%. ILMN’s shares have rallied 194.6% compared with the industry’s 24.6% growth over the past year.